Objectives The coronavirus disease 2019 (COVID-19), caused by the novel betacoronavirus
severe acute respiratory syndrome 2 (SARS-CoV-2), was declared a pandemic in March …

Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited
vaccine supply are ongoing. One strategy that may maximize vaccine coverage and …

Introduction: We evaluated the immunoglobulin (Ig) G antibody response against the
nucleocapsid protein (NP) and the receptor-binding domain (RBD) of the spike protein of …

To the editor, In the pandemic era of COVID-19 and its vaccines, patients on
immunosuppressive medications need special considerations. Immunosuppression can …

The safety and immunogenicity of the two‐dose injections of the CoronaVac vaccine
(Sinovac Life Sciences) have been reported in Phase 1 and 2 trials. 1, 2 After the approval of …

Rapid ramp up of immune responses against SARS-CoV-2 during pandemic enables
adequate prevention and treatment for COVID-19. Estimating levels of SARS-CoV-2 spike …

Background: Measuring the level of antibodies produced post-vaccination in response to the
SARS-CoV-2 spike protein is considered a strategy for estimating the effectiveness of the …

Rapid ramp up of immune responses against SARS-CoV-2 during pandemic enables
adequate prevention and treatment for COVID-19. Estimating levels of SARS-CoV-2 spike …

Background Vaccination for COVID-19 in healthcare workers (HCW) is essential to protect
one of the populations most exposed to this disease. However, data on the humoral …

We use census data at the US county-level to provide causal evidence of the long-term
health benefits of COVID-19 vaccines for elderly vis-à-vis younger adults. We use triple …